CIP2A Promotes Proliferation of Spermatogonial Progenitor Cells and Spermatogenesis in Mice

View/ Open
Author
Ventelä, Sami
Côme, Christophe
Mäkelä, Juho-Antti
Hobbs, Robin M.
Mannermaa, Leni
Kallajoki, Markku
Chan, Edward K.
Toppari, Jorma
Westermarck, Jukka
Published Version
https://doi.org/10.1371/journal.pone.0033209Metadata
Show full item recordCitation
Ventelä, Sami, Christophe Côme, Juho-Antti Mäkelä, Robin M. Hobbs, Leni Mannermaa, Markku Kallajoki, Edward K. Chan, Pier Paolo Pandolfi, Jorma Toppari, and Jukka Westermarck. 2012. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PLoS ONE 7(3): e33209.Abstract
Protein phosphatase 2A (PP2A) is a critical regulator of protein serine/threonine phosphorylation. However, the physiological and developmental roles of different PP2A complexes are very poorly understood. Here, we show that a newly characterized PP2A inhibitory protein CIP2A is co-expressed with ki-67 and with self-renewal protein PLZF in the spermatogonial progenitor cell (SPC) population in the testis. CIP2A and PLZF expression was shown also to correlate Ki-67 expression in human testicular spermatogonia. Functionally, CIP2A mutant mouse testes exhibited smaller number of PLZF-positive SPCs and reduced sperm counts. Moreover, seminiferous tubuli cells isolated from CIP2A mutant mice showed reduced expression of Plzf and other renewal genes Oct-4 and Nanog at mRNA level. However, PLZF-deficient testes did not show altered CIP2A expression. Importantly, spermatogonia-specific restoration of CIP2A expression rescued PLZF expression and sperm production defects observed in CIP2A mutant mice. Taken together, these results reveal first physiological function for an emerging human oncoprotein CIP2A, and provide insights into maintenance of PLZF-positive progenitors. Moreover, demonstration that CIP2A expression can be systematically inhibited without severe consequences to normal mouse development and viability may have clinical relevance regarding targeting of oncogenic CIP2A for future cancer therapies.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312892/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10318215
Collections
- HMS Scholarly Articles [17875]
Contact administrator regarding this item (to report mistakes or request changes)